{"schema_version":"secwatch.filing_event.v1","accession":"0000927066-23-000175","form_type":"8-K","ticker":"DVA","cik":"0000927066","company_name":"DAVITA INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.066291+00:00","generated_at":"2026-06-12T10:46:19.559628+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DaVita reports Q2 2023 revenue of $3.0B; diluted EPS $1.91, adjusted EPS $2.08","bullets":["Consolidated revenue $3.0B; operating income $405M; adjusted operating income $432M.","Diluted GAAP EPS $1.91; adjusted diluted EPS $2.08; free cash flow $260M.","Refinanced existing term loan and revolver with new $1.25B Term Loan A-1 and $1.5B revolver.","Six-month net income $294M vs $387M in prior year, a 24% decline.","CEO highlights strong clinical innovation and operational improvements; reaffirms full-year outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0000927066-23-000175","json":"https://secwatch.observer/filing/0000927066-23-000175.json","markdown":"https://secwatch.observer/filing/0000927066-23-000175.md","text":"https://secwatch.observer/filing/0000927066-23-000175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/927066/000092706623000175/0000927066-23-000175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/927066/000092706623000175/dva-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:46:19.559628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"901f42fa1b69dcb6d9cf52a7cb77f0ee07b1e497","claim":"DAVITA INC. reported the quarter ended June 30, 2023 results: revenue $3.0 billion, net income $179 million, EPS $1.91.","evidence_excerpt":"to deliver strong clinical outcomes and financial results for the year.\" Financial and operating highlights for the quarter ended June 30, 2023: • Consolidated revenues were $3.0 billion. • Operating income was $405 million and adjusted operating income was $432 million. • Diluted earnings per share was $1.91 and adjusted diluted earnings per share was $2.08. •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/927066/000092706623000175/0000927066-23-000175-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$3.0 billion"},{"label":"Net income","value":"$179 million"},{"label":"EPS","value":"$1.91"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}